Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

NCT05175235 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05175235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05175235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 19, 2021
Completion date
August 1, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor